The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pemetrexed (Pem), carboplatin (Cb), and bevacizumab (Bev) in patients with nonsquamous NSCLC without or with activating EGFR mutation (CJLSG0909/0910).
 
Tomoki Kimura
Honoraria - Chugai Pharma; Daiichi Sankyo; Lilly; Nippon Boehringer Ingelheim; Novartis; Pfizer; Taiho Pharmaceutical; Takeda; Teijin Pharma
 
Hiroyuki Taniguchi
Honoraria - Abbott Japan; Asahi Kasei; AstraZeneca; Bayer; Chugai Pharma; Daiichi Sankyo; Eisai; Fukuda Denshi; GlaxoSmithKline; Kyorin; Lilly; Meiji Seika Kaisha; Merck Sharp & Dohme; Nippon Boehringer Ingelheim; Nippon Shinyaku; Novartis; Ono Pharmaceutical; Pfizer; Philips Respironics; Shionogi; Taiho Pharmaceutical; Teijin Pharma; TERUMO
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Nippon Boehringer Ingelheim; Olympus
 
Tomohiko Ogasawara
No Relationships to Disclose
 
Masashi Kondo
Honoraria - AstraZeneca; Chugai Pharma; Lilly; Nippon Boehringer Ingelheim; Pfizer
Research Funding - Chugai Pharma (Inst); Lilly; Nippon Boehringer Ingelheim (Inst); Pfizer
 
Ryujiro Suzuki
No Relationships to Disclose
 
Masashi Yamamoto
No Relationships to Disclose
 
Joe Shindo
No Relationships to Disclose
 
Osamu Hataji
Honoraria - Novartis
Research Funding - GlaxoSmithKline (Inst); Kyorin (Inst); Nippon Boehringer Ingelheim (Inst); Novartis (Inst)
 
Norio Yoshida
No Relationships to Disclose
 
Eiji Kojima
No Relationships to Disclose
 
Yoshinori Hasegawa
No Relationships to Disclose
 
Hiroshi Saito
Stock and Other Ownership Interests - Bristol-Myers Squibb Japan; Sawai Pharmaceutical Co; Takeda
Honoraria - AstraZeneca; Chugai Pharma; Lilly; Nippon Boehringer Ingelheim; Nippon Kayaku; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Daiichi Sankyo; Merck Serono; Ono Pharmaceutical; Sumitomo Dainippon; Taiho Pharmaceutical